120167-35-3 Usage
Uses
Used in Pharmaceutical Industry:
(S)-(-)-Mosapramine is used as an antidepressant and anxiolytic medication for treating depression and anxiety disorders. Its mechanism of action involves increasing the levels of serotonin in the brain, which helps improve mood and reduce anxiety.
Used in Neurodegenerative Disorder Treatment:
(S)-(-)-Mosapramine is used as a potential therapeutic agent for various neurodegenerative disorders due to its neuroprotective and neurotrophic properties. These characteristics may aid in the development of treatments for conditions such as Alzheimer's disease, Parkinson's disease, and other related disorders.
Used in Neuroscience and Neuropharmacology Research:
(S)-(-)-Mosapramine is used as a subject of study in the fields of neuroscience and neuropharmacology to better understand its therapeutic potential and mechanisms of action. Further research may reveal additional applications and insights into the compound's effects on the brain and nervous system.
Check Digit Verification of cas no
The CAS Registry Mumber 120167-35-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,1,6 and 7 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 120167-35:
(8*1)+(7*2)+(6*0)+(5*1)+(4*6)+(3*7)+(2*3)+(1*5)=83
83 % 10 = 3
So 120167-35-3 is a valid CAS Registry Number.
120167-35-3Relevant academic research and scientific papers
Syntheses and biological activities of optical isomers of 3-chloro-5-[3- (2-oxo-1,2,3,5,6,7,8,8a-octahydroimidazo[1,2-α]pyridine-3-spiro-4'- piperidino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine (Mosapramine) dihydrochloride
Lashiro,Seioguchi,Fukuda,Marubayashi
, p. 1074 - 1078 (2007/10/02)
Mosapramine (1) is a new neuroleptic drug with an asymmetric carbon atom (8a) in its imidazopyridine ring. The enantiomers of this agent were synthesized to compare their biological activities, such as antiapomorphine activity, affinity for dopamine D2 receptor and acute toxicity. The key intermediates, (R)-(-)- and (S)-(+)-2-oxo-1,2,3,5,6,7,8,8a- octahydroimidazo[1,2-α]pyridine-3-spiro-4'-piperidines, were prepared by optical resolution of the corresponding (±)-compound and were treated with 3-chloro-5-(3-methanesulfonyloxypropyl)-10,11-dihydro-5H-dibenz[b,f]azepine to afford (R)-(-)-1 and (S)-(+)-1, respectively. There were few differences in the examined biological activities of the two enantiomers as their dihydrochlorides.
